HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Phase II study of Edatrexate in stage III and IV non-small-cell lung cancer.

Abstract
A total of 49 patients with advanced, previously untreated non-small-cell lung cancer (NSCLC) were treated with a new antifolate, Edatrexate (10-ethyl-10-deaza-aminopterin; 10-EdAM). Patients received 80 mg/m2 weekly for 12 weeks, and responders received a further 6 cycles at 2-week intervals. Dose reductions were carried out for haematological toxicity and mucositis. Response was assessed prior to each treatment according to WHO criteria. Among the 45 evaluable patients, 6 [13.3%; 95% confidence interval (CI), 6%-26%] achieved a partial response (PR) and 9 (20%; 95% CI, 11%-34%) showed a minor response (MR; 25%-50% reduction in the sum of 2 perpendicular tumour diameters). In those receiving four or more cycles of treatment, the PR and MR rates were 17.6% and 26.4%, respectively. The resultant toxicity mainly constituted skin rash, mucositis and myelosuppression. Edatrexate is active against NSCLC and produces toxicity profile similar to that of methotrexate.
AuthorsR L Souhami, R M Rudd, S G Spiro, R Allen, P Lamond, P G Harper
JournalCancer chemotherapy and pharmacology (Cancer Chemother Pharmacol) Vol. 30 Issue 6 Pg. 465-8 ( 1992) ISSN: 0344-5704 [Print] Germany
PMID1327568 (Publication Type: Clinical Trial, Clinical Trial, Phase II, Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • edatrexate
  • Aminopterin
Topics
  • Aged
  • Aminopterin (adverse effects, analogs & derivatives, pharmacology)
  • Carcinoma, Non-Small-Cell Lung (drug therapy, pathology)
  • Drug Administration Schedule
  • Female
  • Humans
  • Lung Neoplasms (drug therapy, pathology)
  • Male
  • Neoplasm Staging

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: